US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
JP2919890B2
(ja)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
EP2261229A3
(en)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
JP2003512019A
(ja)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
変化したエフェクター機能を有するポリペプチド変異体
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
MXPA02003456A
(es)
|
1999-10-04 |
2002-10-23 |
Medicago Inc |
Metodo para regular la transcripcion de genes foraneos.
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
WO2001044463A1
(en)
|
1999-12-15 |
2001-06-21 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
EP1254108A1
(en)
|
2000-01-24 |
2002-11-06 |
MERCK SHARP & DOHME LTD. |
Gamma-secretase inhibitors
|
GB0005251D0
(en)
|
2000-03-03 |
2000-04-26 |
Merck Sharp & Dohme |
Therapeutic compounds
|
GB0008710D0
(en)
|
2000-04-07 |
2000-05-31 |
Merck Sharp & Dohme |
Therapeutic compounds
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
CA2953239A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
EP1334085B1
(en)
|
2000-11-02 |
2005-08-24 |
Merck Sharp & Dohme Ltd. |
Sulfamides as gamma-secretase inhibitors
|
CN101940189A
(zh)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
WO2003085119A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
AU2003239966B9
(en)
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
GB0223038D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
GB0223039D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0225474D0
(en)
|
2002-11-01 |
2002-12-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
PL212899B1
(pl)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
|
EP1585767A2
(en)
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
HUE031632T2
(en)
|
2003-11-05 |
2017-07-28 |
Roche Glycart Ag |
Antigen binding molecules with enhanced Fc receptor binding affinity and effector function
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
GB0326039D0
(en)
|
2003-11-07 |
2003-12-10 |
Merck Sharp & Dohme |
Therapeutic agents
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
JP5128935B2
(ja)
|
2004-03-31 |
2013-01-23 |
ジェネンテック, インコーポレイテッド |
ヒト化抗TGF−β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP2360186B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
ZA200704794B
(en)
*
|
2004-11-10 |
2008-09-25 |
Hubrecht Lab |
Treatment of an instestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
|
EP1824503A1
(en)
|
2004-11-10 |
2007-08-29 |
Hubrecht Laboratorium |
Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
TW200812616A
(en)
|
2006-05-09 |
2008-03-16 |
Genentech Inc |
Binding polypeptides with optimized scaffolds
|
MX2008015541A
(es)
|
2006-06-06 |
2008-12-18 |
Genentech Inc |
Anticuerpos anti-dll4 y metodos que los usan.
|
US7919092B2
(en)
|
2006-06-13 |
2011-04-05 |
Oncomed Pharmaceuticals, Inc. |
Antibodies to notch receptors
|
PL2059533T3
(pl)
|
2006-08-30 |
2013-04-30 |
Genentech Inc |
Przeciwciała wieloswoiste
|
SG174100A1
(en)
|
2006-09-08 |
2011-09-29 |
Genentech Inc |
Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
|
CA2666672A1
(en)
|
2006-10-19 |
2008-05-02 |
Genentech, Inc. |
Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
|
WO2008136848A2
(en)
|
2006-10-19 |
2008-11-13 |
Genentech Inc. |
Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
EP2125887A4
(en)
|
2007-01-24 |
2010-11-10 |
Oncomed Pharm Inc |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
|
US8802103B2
(en)
|
2007-05-15 |
2014-08-12 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
WO2009035522A1
(en)
|
2007-09-14 |
2009-03-19 |
Albert Einstein College Of Medicine Of Yeshiva University |
Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
|
US8715941B2
(en)
|
2007-11-16 |
2014-05-06 |
Arca Biopharma, Inc. |
Antibodies to LRP6
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
BRPI0913119A2
(pt)
|
2008-05-27 |
2015-07-28 |
Univ Texas |
Inibidores de sinalização de proteína wnt
|
US8834875B2
(en)
|
2010-01-13 |
2014-09-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
EP2307459B1
(en)
|
2008-07-08 |
2015-01-07 |
OncoMed Pharmaceuticals, Inc. |
Notch1 receptor binding agents and methods of use thereof
|
KR20110057244A
(ko)
|
2008-09-19 |
2011-05-31 |
메디뮨 엘엘씨 |
Dll4에 대한 항체 및 이의 용도
|
RU2579897C2
(ru)
|
2008-09-26 |
2016-04-10 |
Онкомед Фармасьютикалс, Инк. |
Агенты, связывающие рецептор "frizzled", и их применение
|
US20130295106A1
(en)
|
2008-09-26 |
2013-11-07 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-Binding Agents And Uses Thereof
|
US8404239B2
(en)
|
2008-10-01 |
2013-03-26 |
Genentech, Inc. |
Anti-Notch2 NRR antibodies
|
WO2010146550A1
(en)
|
2009-06-18 |
2010-12-23 |
Pfizer Inc. |
Anti notch-1 antibodies
|
JP5903382B2
(ja)
|
2009-08-29 |
2016-04-13 |
アッヴィ・インコーポレイテッド |
治療用dll4結合タンパク質
|
KR101782180B1
(ko)
|
2009-09-30 |
2017-10-23 |
제넨테크, 인크. |
Notch3 길항제를 사용한 Notch1―길항제-내성 암(들)의 치료
|
WO2011063237A2
(en)
|
2009-11-19 |
2011-05-26 |
Oncomed Pharmaceuticals, Inc. |
Jagged-binding agents and uses thereof
|
SI3001903T1
(en)
|
2009-12-21 |
2018-02-28 |
Samumed, Llc |
1H-pyrazolo (3,4-b) pyridines and their therapeutic uses
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
EP2523974A4
(en)
|
2010-01-12 |
2013-11-06 |
Oncomed Pharm Inc |
WNT BINDING AGENTS AND USES THEREOF
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
MX347515B
(es)
|
2010-04-01 |
2017-04-28 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen al receptor encrespado y usos de los mismos.
|
SG185415A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
EP2638025B1
(en)
|
2010-11-12 |
2020-02-05 |
Deutsches Krebsforschungszentrum (DKFZ) |
Chromene derivatives and their analoga as wnt pathway antagonists
|
US20130323265A1
(en)
|
2010-11-15 |
2013-12-05 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancer with dll4 antagonists
|
WO2012076898A1
(en)
|
2010-12-08 |
2012-06-14 |
Oslo University Hospital Hf |
Triazole derivatives as wnt signaling pathway inhibitors
|
EP2651971A1
(en)
|
2010-12-14 |
2013-10-23 |
The United States of America, as Represented By the Secretery, Department of Health and Human Services |
Synthetic peptide inhibitors of wnt pathway
|
KR20150088334A
(ko)
|
2010-12-15 |
2015-07-31 |
와이어쓰 엘엘씨 |
항-노치1 항체
|
US20140005164A1
(en)
|
2011-04-04 |
2014-01-02 |
Siena Biotech S.P.A. |
Wnt pathway antagonists
|
US8790650B2
(en)
|
2011-04-28 |
2014-07-29 |
Vanderbilt University |
Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
AU2012295394B2
(en)
|
2011-08-12 |
2016-04-14 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
PT2758073T
(pt)
|
2011-09-23 |
2019-02-01 |
Oncomed Pharm Inc |
Agentes de ligação a vegf/dll4 e utilizações dos mesmos
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
US9403800B2
(en)
|
2012-01-24 |
2016-08-02 |
Chemregen, Inc. |
Compounds for inhibition of cancer cell proliferation
|
CN104718220A
(zh)
|
2012-02-11 |
2015-06-17 |
霍夫曼-拉罗奇有限公司 |
R-spondin易位及其使用方法
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
WO2013173542A1
(en)
|
2012-05-16 |
2013-11-21 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancer with notch2/3 antibodies
|
JP2015520172A
(ja)
|
2012-05-31 |
2015-07-16 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Dll−4に結合する抗原結合蛋白質
|
RU2015101803A
(ru)
|
2012-06-22 |
2016-08-20 |
Сайтомкс Терапьютикс, Инк. |
Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
|
SG11201500233PA
(en)
|
2012-07-13 |
2015-04-29 |
Oncomed Pharm Inc |
Rspo3 binding agents and uses thereof
|
CN104520328B
(zh)
|
2012-08-13 |
2019-06-07 |
霍夫曼-拉罗奇有限公司 |
抗锯齿蛋白抗体及使用方法
|
JP2014086920A
(ja)
|
2012-10-24 |
2014-05-12 |
Toshiba Corp |
テレビジョン受像機、電子機器、および基板アセンブリ
|
GB201300706D0
(en)
|
2013-01-15 |
2013-02-27 |
Cancer Rec Tech Ltd |
Antibody
|